Mobile app to track symptoms and treatment in IgA nephropathy patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to capture the full spectrum of symptoms, treatment patterns, and health-related quality of life (HRQoL) in patients with Immunoglobulin A nephropathy (IgAN) using the Folia Health platform. Participants will enroll through a mobile app, complete an initial 6-month data collection period involving surveys and monthly check-ins, and can continue tracking their health outcomes for personal use afterward. The data collected may also be integrated with Novartis's APPRISE data platform for further analysis over two years.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of IgAN, regardless of symptom or treatment history
* Adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age
* US-based with a proficient understanding of and ability to read the English language

Exclusion Criteria:

None

Where it's running

• Novartis Investigational site
  Boston, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: +41613241111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Atrasentan for pediatric primary IgA nephropathy

  This study tests whether atrasentan can help children and teens with primary IgA nephropathy reduce protein in urine.

  Recruiting at 19 sites Phase 3 Novartis · Neptune City, New Jersey and 22 other locations · NCT07498335

• MIL116 for people with IgA nephropathy and healthy volunteers

  This trial will test whether subcutaneous MIL116, an anti‑APRIL antibody, is safe and how it behaves in the body in adults with IgA nephropathy and in healthy volunteers.

  Recruiting Phase 1/2 Beijing Mabworks Biotech Co., Ltd. · Beijing · NCT07375758

• Ravulizumab for children with IgA nephropathy or IgA vasculitis nephritis

  This trial will test whether intravenous ravulizumab is safe and changes disease markers in children aged 2 to under 18 with biopsy‑proven IgA nephropathy or IgA vasculitis nephritis.

  Recruiting at 13 sites Phase 3 Alexion Pharmaceuticals, Inc. · Palo Alto, California and 14 other locations · NCT07024563

• Iptacopan added to standard care to change kidney biopsy findings in adults with IgA nephropathy

  This will try iptacopan added to standard treatment for adults with biopsy-confirmed IgA nephropathy to see if it reduces mesangial complement (C3c) deposits and improves kidney biomarkers over 9 months.

  Recruiting at 19 sites Phase 2 Novartis · Birmingham, Alabama and 18 other locations · NCT06797518

• Treatment of pediatric kidney diseases with Sparsentan

  This study is testing if a new oral medication called Sparsentan can help children aged 1 to 18 with certain kidney diseases feel better and improve their condition over two years.

  Recruiting at 38 sites Phase 2 Travere Therapeutics, Inc. · Los Angeles, California and 46 other locations · NCT05003986

• Sparsentan for IgA Nephropathy: safety and activity in adults with incident IgAN and recurrent IgAN after transplant

  This trial tests whether sparsentan can be safely given and help kidney outcomes in adults with immunoglobulin A nephropathy, including people newly diagnosed who haven’t had ACEI/ARB therapy and people with recurrent IgAN after kidney transplant.

  Recruiting at 6 sites Phase 2 University of Leicester · Cambridge, England and 5 other locations · NCT04663204

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.